Get the Stockscreener App
203.08
4.00%
7.81
After Hours:
203.08
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $203.08, with a volume of 1.14M.
It is up +4.00% in the last 24 hours and up +1.39% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
See More
Previous Close:
$195.27
Open:
$197.29
24h Volume:
1.14M
Relative Volume:
0.76
Market Cap:
$29.46B
Revenue:
$5.54B
Net Income/Loss:
$1.52B
P/E Ratio:
19.58
EPS:
10.3734
Net Cash Flow:
$1.74B
1W Performance:
+2.25%
1M Performance:
+1.39%
6M Performance:
-20.52%
1Y Performance:
-26.20%
1-Day Range:
$195.79
$203.58
1-Week Range:
$190.21
$203.58
52-Week Range:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
203.08 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
356.83 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
158.92 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
39.70 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.28 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | JP Morgan | Overweight |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Is It Too Late to Buy ResMed Inc (RMD) After 4.0% Rally? GF Value Says Undervalued - GuruFocus
Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ResMed (ASX:RMD) Dividend Outlook: What Income Investors Are Watching? - Kalkine
Resmed Inc (RMD) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed stock steadies as sleep-apnea demand supports earnings and growth - AD HOC NEWS
Resmed Inc (RMD) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed Inc. (RMD) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Resmed Inc (RMD) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Resmed Inc (RMD) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Earnings Dates, Call Summary & Reports - TipRanks
RESMED INC. R (RMEA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
ResMed stock advances on its latest earnings backdrop. - AD HOC NEWS
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
J.P. Morgan Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Catapult Sports, Hazer Group & ResMed - marketscreener.com
Resmed Inc (0KW4) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed stock trades near recent lows as investors assess obesity drug impact and earnings momentum - Ad-hoc-news.de
Resmed Inc (0KW4) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not - Trefis
ResMed (ASX:RMD) Moves Lower Today — Is the Sleep Apnoea Giant Still Worth Watching? - Kalkine
Canaccord Genuity Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed stock steadies as investors weigh sleep apnea demand and recent earnings - Ad-hoc-news.de
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
ResMed Stock Is Down 30% From Its Peak While Free Cash Flow Just Hit a Record $1.7 Billion - TIKR.com
ResMed stock steadies as sleep apnea demand supports earnings growth - Ad-hoc-news.de
ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says - Moomoo
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE - marketscreener.com
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) - TradingView
ResMed stock trades near record territory as sleep apnea demand drives revenue growth - Ad-hoc-news.de
UBS lowers ResMed stock price target to $300 on valuation - Investing.com UK
UBS lowers ResMed stock price target to $300 on valuation By Investing.com - Investing.com Nigeria
ResMed stock trades near recent highs as sleep apnea demand supports growth - Ad-hoc-news.de
Can ResMed (ASX:RMD) Reignite Growth by Slimming Down? - Kalkine Media
ResMed sharpens focus with a strategic sale: The Shift Few Are Watching - Kalkine Media
ResMed Target Price Cut 10% to A$40.00/Share by Canaccord Genuity>RMD.AU - Moomoo
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief Australia: EQ Resources, ResMed Inc, BHP Group Ltd and more - Smartkarma
RMD stock holds after latest ResMed results - ad-hoc-news.de
ResMed stock steadies as investors weigh obesity drug impact and solid earnings base - Ad-hoc-news.de
ResMed stock steadies as investors weigh growth and margins after recent quarterly update - ad-hoc-news.de
ResMed stock trades steady as sleep apnea demand supports earnings - ad-hoc-news.de
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Is ResMed Stock a Buy After the Noctrix Acquisition? - TIKR.com
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):